Abstract
Aging is associated with deficits in several cognitive domains as well as a decline in brain dopamine activity. Catechol-O-methyl transferase (COMT), an enzyme involved in the degradation of dopamine, is a critical determinant of the availability of this neurotransmitter in the prefrontal cortex. A functional single nucleotide polymorphism in the COMT gene, Val158Met, modulates the activity of this enzyme and affects cognition and the brain regions underlying this function. The effects of COMT Val158Met polymorphism are magnified in the aging brain. Here, we review the evidence supporting a role of COMT genetic variation in cognitive as well as structural and functional brain changes associated with senescence. We will address the potential modulatory role of genetic and non-genetic factors on the neural and cognitive effects of COMT Val158Met in late life. Furthermore, we will discuss the viability of a COMT-targeted treatment for improving cognitive efficiency in aging.
Keywords: Catechol-O-methyl transferase, dopamine, aging, cognition, catechol-O-methyl transferase inhibitors, COMT Inhibitors, COMT, Working memory, functional magnetic resonance imaging, Dopamine transporter, val158Met, BDNF-Met, ACE Inhibitors
CNS & Neurological Disorders - Drug Targets
Title:Catechol-O-Methyl Transferase Modulates Cognition in Late Life: Evidence and Implications for Cognitive Enhancement
Volume: 11 Issue: 3
Author(s): Fabio Sambataro, Maria Pennuto and Robert Christian Wolf
Affiliation:
Keywords: Catechol-O-methyl transferase, dopamine, aging, cognition, catechol-O-methyl transferase inhibitors, COMT Inhibitors, COMT, Working memory, functional magnetic resonance imaging, Dopamine transporter, val158Met, BDNF-Met, ACE Inhibitors
Abstract: Aging is associated with deficits in several cognitive domains as well as a decline in brain dopamine activity. Catechol-O-methyl transferase (COMT), an enzyme involved in the degradation of dopamine, is a critical determinant of the availability of this neurotransmitter in the prefrontal cortex. A functional single nucleotide polymorphism in the COMT gene, Val158Met, modulates the activity of this enzyme and affects cognition and the brain regions underlying this function. The effects of COMT Val158Met polymorphism are magnified in the aging brain. Here, we review the evidence supporting a role of COMT genetic variation in cognitive as well as structural and functional brain changes associated with senescence. We will address the potential modulatory role of genetic and non-genetic factors on the neural and cognitive effects of COMT Val158Met in late life. Furthermore, we will discuss the viability of a COMT-targeted treatment for improving cognitive efficiency in aging.
Export Options
About this article
Cite this article as:
Sambataro Fabio, Pennuto Maria and Christian Wolf Robert, Catechol-O-Methyl Transferase Modulates Cognition in Late Life: Evidence and Implications for Cognitive Enhancement, CNS & Neurological Disorders - Drug Targets 2012; 11 (3) . https://dx.doi.org/10.2174/187152712800672463
DOI https://dx.doi.org/10.2174/187152712800672463 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Atorvastatin May Correct Dyslipidemia in Adult Patients at Risk for Alzheimer’s Disease Through an Anti-Inflammatory Pathway
CNS & Neurological Disorders - Drug Targets SUBJECT INDEX TO VOLUME 1
Current Drug Safety GABA Targets for the Treatment of Cognitive Dysfunction in Schizophrenia
Current Neuropharmacology BRI2 Interacts with BACE1 and Regulates Its Cellular Levels by Promoting its Degradation and Reducing Its mRNA Levels
Current Alzheimer Research Chemical Analysis of the Chinese Herbal Medicine Turmeric (Curcuma longa L.)
Current Pharmaceutical Analysis Non-Canonical Peptides Bound to MHC
Current Pharmaceutical Design Opioid Regulation of Mu Receptor Internalisation: Relevance to the Development of Tolerance and Dependence
CNS & Neurological Disorders - Drug Targets Reversal of Metabolic and Neurological Symptoms of Phenylketonuric Mice Treated with a PAH Containing Helper-Dependent Adenoviral Vector
Current Gene Therapy Transglutaminases - Possible Drug Targets in Human Diseases
Current Drug Targets - CNS & Neurological Disorders The Genomic Approaches to Major Depression
Current Pharmacogenomics New Trends of Deep Learning in Clinical Cardiology
Current Bioinformatics An Investigative Approach to Treatment Modalities for Squamous Cell Carcinoma of Skin
Current Drug Delivery Under-Dosing of Etomidate for Rapid Sequence Intubation in the Emergency Department
Current Drug Safety Editorial [Hot Topic:New Approaches for the Treatment of Pain and Inflammation (Guest Editor: Kaustav Biswas)]
Current Topics in Medicinal Chemistry Meet the Editorial Board
Combinatorial Chemistry & High Throughput Screening Combination Treatment in Alzheimers Disease: Results of a Randomized, Controlled Trial with Cerebrolysin and Donepezil
Current Alzheimer Research Efficacy and Mechanisms of Action of Lithium Augmentation in Refractory Major Depression
Current Pharmaceutical Design Identifying Patterns of Psychopathology and Pointing the Way to Effective Interventions
Adolescent Psychiatry Integrative Physiology of Orexins and Orexin Receptors
CNS & Neurological Disorders - Drug Targets Lithium Restores Age-related Olfactory Impairment in the Ts65Dn Mouse Model of Down Syndrome
CNS & Neurological Disorders - Drug Targets